Xspray Pharma AB (publ) (XSPRAY.ST)
SEK 41.5
(-5.36%)
SEK 41.5
(-5.36%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 43.78 Million SEK | 411.94% |
| 2022 | 8.55 Million SEK | 37.96% |
| 2021 | 6.19 Million SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | 100.0% |
| 2018 | -1.67 Million SEK | -7151.08% |
| 2017 | -23.1 Thousand SEK | -100.95% |
| 2016 | 2.43 Million SEK | 1396.41% |
| 2015 | -188 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 43.6 Million SEK | -0.41% |
| 2024 Q2 | 44.5 Million SEK | 2.08% |
| 2023 Q2 | 45.28 Million SEK | 143.57% |
| 2023 Q1 | 18.59 Million SEK | 117.39% |
| 2023 Q4 | 43.78 Million SEK | 1.81% |
| 2023 Q3 | 43 Million SEK | -5.04% |
| 2023 FY | 43.78 Million SEK | 411.94% |
| 2022 Q2 | 6 Million SEK | -3.13% |
| 2022 Q3 | 4.97 Million SEK | -17.15% |
| 2022 Q1 | 6.19 Million SEK | 0.0% |
| 2022 FY | 8.55 Million SEK | 37.96% |
| 2022 Q4 | 8.55 Million SEK | 71.9% |
| 2021 FY | 6.19 Million SEK | 0.0% |
| 2021 Q2 | 1.03 Million SEK | 160.79% |
| 2021 Q3 | 5.83 Million SEK | 462.87% |
| 2021 Q4 | 6.19 Million SEK | 6.2% |
| 2021 Q1 | -1.7 Million SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 FY | - SEK | 100.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | -1.67 Million SEK | -7151.08% |
| 2018 Q1 | - SEK | 100.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | -23.1 Thousand SEK | 0.0% |
| 2017 FY | -23.1 Thousand SEK | -100.95% |
| 2017 Q1 | - SEK | -100.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | 2.43 Million SEK | 0.0% |
| 2016 FY | 2.43 Million SEK | 1396.41% |
| 2015 FY | -188 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | -2189049900.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 1145.142% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 713.523% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | -193.734% |
| Intervacc AB (publ) | 10.48 Million SEK | -317.638% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | 1751340.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | -24.275% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | -382.808% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 2245279.487% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | -1289.873% |
| Saniona AB (publ) | 1.00 SEK | -4378099900.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 2792.558% |
| Biovica International AB (publ) | 2.19 Million SEK | -1890.95% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -4378099900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | -2004.856% |
| Xintela AB (publ) | 398 Thousand SEK | -10900.251% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -6154.429% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 5173.123% |
| Amniotics AB (publ) | 534 Thousand SEK | -8098.689% |
| 2cureX AB (publ) | -1000.00 SEK | 4378200.0% |
| CombiGene AB (publ) | -1.79 Million SEK | 2533.63% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | -114.319% |
| Camurus AB (publ) | 100.95 Million SEK | 56.633% |
| Corline Biomedical AB | -3.85 Million SEK | 1235.105% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -4378000.0% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | 4.28 Million SEK | -922.921% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | -347.11% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 988.233% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | -7929.719% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 9894.714% |
| Nanologica AB (publ) | 2.97 Million SEK | -1372.62% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 13732.783% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | -269.647% |
| Alzinova AB (publ) | -3.27 Million SEK | 1435.601% |
| Oncopeptides AB (publ) | 2.42 Million SEK | -1705.402% |
| Pila Pharma AB (publ) | 1.00 SEK | -4378099900.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 2946331.494% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | -985.3% |
| Simris Alg AB (publ) | 1.09 Million SEK | -3912.924% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | -82.042% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 59.028% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -4158.852% |